DNTH
Dianthus Therapeutics Inc
$
36.280
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
36.630
Open
35.980
VWAP
36.01
Vol
493.71K
Mkt Cap
1.56B
Low
35.320
Amount
17.78M
EV/EBITDA(TTM)
--
Total Shares
29.35M
EV
1.16B
EV/OCF(TTM)
--
P/S(TTM)
428.50
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
327.57K
+69.73%
-0.836
-5.03%
313.29K
-73.06%
-0.824
+0.52%
397.44K
-70%
-1.580
+95.06%
Estimates Revision
The market is revising Downward the revenue expectations for Dianthus Therapeutics, Inc. (DNTH) for FY2025, with the revenue forecasts being adjusted by -6.35% over the past three months. During the same period, the stock price has changed by 93.39%.
Revenue Estimates for FY2025
Revise Downward
-6.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.9%
In Past 3 Month
Stock Price
Go Up
+93.39%
In Past 3 Month
16 Analyst Rating
Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is 67.85 USD with a low forecast of 40.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 36.280
Low
40.00
Averages
67.85
High
100.00
Current: 36.280
Low
40.00
Averages
67.85
High
100.00
Truist
Danielle Brill
Buy
initiated
$56
2025-10-14
Reason
Truist
Danielle Brill
Price Target
$56
2025-10-14
initiated
Buy
Reason
Truist analyst Danielle Brill initiated coverage of Dianthus with a Buy rating and $56 price target. The recent Phase 2 proof-of-concept results with claseprubart in generalized myasthenia gravis were overall supportive of the thesis that Dianthus' differentiated approach to targeting the autoantibody mediated complement cascade may offer similar efficacy as available complement inhibitors, but with a cleaner safety profile, says the analyst, who also thinks the gMG data are relatively de-risking for the ongoing Phase 3 chronic inflammatory demyelinating polyneuropathy trial.
Clear Street
Bill Maughan
initiated
$100
2025-09-16
Reason
Clear Street
Bill Maughan
Price Target
$100
2025-09-16
initiated
Reason
Clear Street analyst Bill Maughan initiated coverage of Dianthus with a Buy rating and $100 price target. Dianthus is a biotech company primarily developing claseprubart for the treatment of complement-driven autoimmune diseases, the analyst tells investors in a research note. The firm believes claseprubart is a "best-in-class" complement inhibitor that is well positioned to improve on the standard of care in each of the three indications currently being tested in the clinic. It sees $1B-$2B of sales potential in each of these opportunities.
Wedbush
Outperform
maintain
$42 -> $44
2025-09-12
Reason
Wedbush
Price Target
$42 -> $44
2025-09-12
maintain
Outperform
Reason
Wedbush raised the firm's price target on Dianthus to $44 from $42 and keeps an Outperform rating on the shares. The firm is incorporating the recent $288M secondary offering into its estimates. Wedbush's model also incorporates the over-allotment and while it previously modeled a raise in early 2026, this would appear to be larger in magnitude versus its prior assumptions. With the proceeds from the offering, Dianthus management anticipates cash/equivalents now extend runway into 2028. With Phase 2 MaGiC data in hand, the firm looks ahead to the second half of 2026 for additional top-line readouts from the claseprubart CIDP and MMN programs.
Stifel
Alex Thompson
Buy
maintain
$52 -> $65
2025-09-12
Reason
Stifel
Alex Thompson
Price Target
$52 -> $65
2025-09-12
maintain
Buy
Reason
Stifel analyst Alex Thompson raised the firm's price target on Dianthus to $65 from $52 and keeps a Buy rating on the shares following the positive Phase 2 MaGic trial in AChR+ Myasthenia Gravis. Following the data, the firm's model now reflects higher MG odds of success of 75%, up from a prior 50% forecast, the analyst noted.
Baird
NULL -> Outperform
upgrade
$50 -> $67
2025-09-09
Reason
Baird
Price Target
$50 -> $67
2025-09-09
upgrade
NULL -> Outperform
Reason
Baird raised the firm's price target on Dianthus to $67 from $50 and keeps an Outperform rating on the shares. The firm said they are positive on the company's Phase 2 MaGic data profile in gMG supporting a differentiated profile.
Raymond James
Outperform
maintain
$56 -> $63
2025-09-09
Reason
Raymond James
Price Target
$56 -> $63
2025-09-09
maintain
Outperform
Reason
Raymond James raised the firm's price target on Dianthus to $63 from $56 and keeps an Outperform rating on the shares. The topline readout for Dianthus's Phase 2 MaGic study evaluating active C1s inhibitor, claseprubart, in acetylcholine receptor generalized myasthenia gravis showed competitive results vs. approved complement therapies on the MG-ADL registrational endpoint, the analyst tells investors in a research note. This result is meaningfully derisking of the CIDP and MMN programs for claseprubart, the firm says.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Dianthus Therapeutics Inc (DNTH.O) is -10.85, compared to its 5-year average forward P/E of -7.64. For a more detailed relative valuation and DCF analysis to assess Dianthus Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.64
Current PE
-10.85
Overvalued PE
-4.92
Undervalued PE
-10.35
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
291.24
Current PS
36.43
Overvalued PS
475.23
Undervalued PS
107.24
Financials
Annual
Quarterly
FY2025Q3
YoY :
-81.77%
396.00K
Total Revenue
FY2025Q3
YoY :
+34.74%
-40.29M
Operating Profit
FY2025Q3
YoY :
+46.04%
-36.77M
Net Income after Tax
FY2025Q3
YoY :
+31.08%
-0.97
EPS - Diluted
FY2025Q3
YoY :
+43.53%
-30.56M
Free Cash Flow
FY2025Q3
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q3
YoY :
+204.94%
-3.56K
FCF Margin - %
FY2025Q3
YoY :
+701.03%
-9.28K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
700.0K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
831.2K
Volume
1
0-12
Months
510.8K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
4
4.5M
Volume
Months
0-12
3
2.9M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
700.0K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DNTH News & Events
Events Timeline
2025-11-05 (ET)
2025-11-05
16:08:28
Dianthus Announces Q3 Earnings Per Share of 97 Cents, Exceeding Consensus Estimate of 90 Cents
2025-10-16 (ET)
2025-10-16
07:05:07
Dianthus Signs Exclusive Licensing Deal with Leads Biolabs for DNTH212
2025-09-09 (ET)
2025-09-09
23:20:37
Dianthus Sets Secondary Offering Price at $33.00 for 6.49 Million Shares
Sign Up For More Events
Sign Up For More Events
News
9.0
10-29NewsfilterDianthus Therapeutics Showcases New Claseprubart Findings at the 2025 AANEM Annual Meeting
3.0
10-16NASDAQ.COM"Understanding the Factors: DFUS on Track for $81"
4.0
09-17TipRanksTop Analysts Recommend 3 Best Stocks to Purchase Now, 9/17/2025
Sign Up For More News
People Also Watch
GRAL
Grail Inc
79.400
USD
-0.82%
IRWD
Ironwood Pharmaceuticals Inc
1.920
USD
-6.34%
KODK
Eastman Kodak Co
7.790
USD
+33.16%
LDI
loanDepot Inc
2.750
USD
+3.77%
CMP
Compass Minerals International Inc
17.170
USD
+3.81%
AUTL
Autolus Therapeutics PLC
1.330
USD
-2.21%
ZJK
ZJK Industrial Co Ltd
2.190
USD
-7.59%
UPB
Upstream Bio Inc
22.960
USD
-2.96%
ACIC
American Coastal Insurance Corp
12.140
USD
-0.41%
FAQ
What is Dianthus Therapeutics Inc (DNTH) stock price today?
The current price of DNTH is 36.28 USD — it has decreased -0.41 % in the last trading day.
What is Dianthus Therapeutics Inc (DNTH)'s business?
What is the price predicton of DNTH Stock?
What is Dianthus Therapeutics Inc (DNTH)'s revenue for the last quarter?
What is Dianthus Therapeutics Inc (DNTH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Dianthus Therapeutics Inc (DNTH)'s fundamentals?
How many employees does Dianthus Therapeutics Inc (DNTH). have?